Access in all areas? A round-up of developments in market access and health technology assessment: part 12
Abstract
In this update we cover the impacts of the US Most Favored Nation pricing policy and research evaluating drug availability and affordability in China as a result of the National Reimbursement Drug List negotiation policy.
Fields of Study & Subjects
Pharmaceutical Economics and Policy
Health Systems
Economic Evaluations
Quality of Life
Healthcare Systems and Reforms
Publication details
- Journal / source
- Journal of Comparative Effectiveness Research
- Publisher
- Becaris Publishing Limited
- Volume
- 15
- Issue
- 2
- Pages
- e250208–e250208
- Publication date
- 7 January 2026
- Language
- EN